Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

NCT01822548 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Vildagliptin
DRUG: Glibenclamide
DRUG: Metformin

Sponsor

Azienda Ospedaliero-Universitaria di Parma